A consortium of new and previous backers led by Life Sciences Partners (LSP) has invested $38.5m in France-based DNA Script, a manufacturer of synthetic DNA.
Calucem reports a turnover of EUR 58m, with an EBITDA of EUR 16m
Should Apex make a firm offer, Cinven would have to significantly up its own bid for the fund administrator
Third exit announced by Lonsdale this year, and the second from its 2016 fund
Paris-based private equity firm is exploring options around a dual-track process